A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic squamous non-small cell lung cancer that cannot be cured with surgery or radiation.
- You have tried platinum chemo combined with or followed by immunotherapy, and your cancer got worse.
- You are at least 18 years old and willing to sign a consent form.
- You have at least one measurable tumor on a scan, and you can provide a tumor tissue sample for testing.
- You have not had certain prior treatments, like topoisomerase I meds, docetaxel, or recent radiation to a large area.
- You are in good enough health, with no uncontrolled infections, heart issues, or other serious lung diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Hear when a new Advanced or Metastatic Squamous Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.